AI business Recursion Pharmaceuticals has narrowed its drug development pipeline, ending or pausing five programmes as it seeks to reduce costs and reprioritise resources following a merger with ...

The process should be supervised by a court-appointed official and allow the DOJ to approve or reject potential buyers “This comprehensive set of remedies…is necessary to terminate Google’s ...

NEW YORK, Aug 8 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab, a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to ...

WASHINGTON, Feb 26 (Reuters) - U.S. President Donald Trump issued an executive order on Wednesday aimed at implementing the Department of Government Efficiency's cost-cutting drive, the White ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed ...

WASHINGTON — The Supreme Court on Friday allowed the Trump administration to terminate Education Department grants for teacher training that officials deemed to violate their new policy opposing ...